Does MS Drug Dosing Regimen Need Revising?

B cell depletion can last well past the 6-month dosing regimen typically used with ocrelizumab or rituximab for multiple sclerosis or neuromyelitis optica spectrum disorders, new research suggests.
Medscape Medical News